1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
2.
|
Johansson SL and Cohen SM: Epidemiology
and etiology of bladder cancer. Semin Surg Oncol. 13:291–298. 1997.
View Article : Google Scholar : PubMed/NCBI
|
3.
|
Tran E, Souhami L, Tanguay S and Rajan R:
Bladder conservation treatment in the elderly population: results
and prognostic factors of muscle-invasive bladder cancer. Am J Clin
Oncol. 32:333–337. 2009. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Weizer AZ, Joshi D, Daignault S, et al:
Performance status is a predictor of overall survival of elderly
patients with muscle invasive bladder cancer. J Urol.
177:1287–1293. 2007. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Hoshi S, Shintaku I, Suzuki K, et al:
Bladder preservation by internal iliac arterial infusion
chemotherapy and irradiation in T3 bladder carcinoma patients over
the age of 70 years. Tohoku J Exp Med. 192:249–258. 2000.PubMed/NCBI
|
6.
|
Kaufman DS, Winter KA, Shipley WU, et al:
The initial results in muscle-invading bladder cancer of RTOG
95-06: phase I/II trial of transurethral surgery plus radiation
therapy with concurrent cisplatin and 5-fluorouracil followed by
selective bladder preservation or cystectomy depending on the
initial response. Oncologist. 5:471–476. 2000.
|
7.
|
Rodel C, Grabenbauer GG, Kuhn R, et al:
Combined-modality treatment and selective organ preservation in
invasive bladder cancer: long-term results. J Clin Oncol.
20:3061–3071. 2002. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Shipley WU, Winter KA, Kaufman DS, et al:
Phase III trial of neoadjuvant chemotherapy in patients with
invasive bladder cancer treated with selective bladder preservation
by combined radiation therapy and chemotherapy: initial results of
Radiation Therapy Oncology Group 89-03. J Clin Oncol. 16:3576–3583.
1998.
|
9.
|
Tester W, Caplan R, Heaney J, et al:
Neoadjuvant combined modality program with selective organ
preservation for invasive bladder cancer: results of Radiation
Therapy Oncology Group phase II trial 8802. J Clin Oncol.
14:119–126. 1996.
|
10.
|
Hagan MP, Winter KA, Kaufman DS, et al:
RTOG 97-06: initial report of a phase I–II trial of selective
bladder conservation using TURBT, twice-daily accelerated
irradiation sensitized with cisplatin, and adjuvant MCV combination
chemotherapy. Int J Radiat Oncol Biol Phys. 57:665–672.
2003.PubMed/NCBI
|
11.
|
Kaufman DS, Winter KA, Shipley WU, et al:
Phase I–II RTOG study (99-06) of patients with muscle-invasive
bladder cancer undergoing transurethral surgery, paclitaxel,
cisplatin, and twice-daily radiotherapy followed by selective
bladder preservation or radical cystectomy and adjuvant
chemotherapy. Urology. 73:833–837. 2009.
|
12.
|
Azuma H, Inamoto T, Ibuki N, et al: Novel
bladder preservation therapy for locally invasive bladder cancer:
combined therapy using balloon-occluded arterial infusion of
anticancer agent and hemodialysis with concurrent radiation. Int J
Oncol. 37:773–785. 2010. View Article : Google Scholar
|
13.
|
Greene FL, Page DL, Fleming ID, Fritz A,
Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Manual. 6th
edit. Springer Verlag; New York, NY: 2002, View Article : Google Scholar
|
14.
|
Ficcara V, Dalpiaz O, Alrabi N, Novara G,
Galfano A and Artibani W: Correlation between clinical and
pathological staging in a series of radical cystectomies for
bladder carcinoma. BJU Int. 95:786–790. 2005. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Azuma H, Inamoto T, Ibuki N, et al:
Utility of the novel bladder preservation therapy,
BOAI-CDDP-radiation (OMC-regimen), for elderly patients with
invasive bladder cancer. Int J Oncol. 38:13–24. 2011.PubMed/NCBI
|
16.
|
Nielsen ME, Shariat SF, Karakiewicz PI, et
al: Advanced age is associated with poorer bladder cancer-specific
survival in patients treated with radical cystectomy. Eur Urol.
51:699–708. 2007. View Article : Google Scholar
|
17.
|
Collins JM: Pharmacokinetic rationale for
intraarterial therapy. Cancer Chemotherapy, Challenges for the
Future. 4. Kimura K: Excerpta Medica; Amsterdam: 1989
|
18.
|
Mitsuzane K, Kawabata M, Terada M, Nomura
S, Sato M and Yamada R: Balloon-occluded arterial infusion as
chemotherapy in bladder cancer-long-term results. Gan To Kagaku
Ryoho. 17:1701–1704. 1990.(In Japanese).
|
19.
|
Cvitkovic E, Spaulding J, Bethune V,
Martin J and Whitmore WF: Improvement of
cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an
animal model. Cancer. 39:1357–1361. 1977. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Douple EB and Richmond RC: A review of
platinum complex biochemistry suggests a rationale for combined
platinum-radiotherapy. Int J Radiat Oncol Biol Phys. 8:1335–1339.
1979. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Abbott DW, Freeman ML and Holt JT:
Double-strand break repair deficiency and radiation sensitivity in
BRCA2 mutant cancer cells. J Natl Cancer Inst. 90:978–985. 1998.
View Article : Google Scholar : PubMed/NCBI
|
22.
|
Belt RJ, Himmelstein KJ, Patton TF,
Bannister SJ, Sternson LA and Repta AJ: Pharmacokinetics of
non-protein-bound platinum species following administration of
cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 63:1515–1521.
1979.PubMed/NCBI
|
23.
|
Himmelstein KJ, Patton TF, Belt RJ, Taylor
S, Repta AJ and Sternson LA: Clinical kinetics on intact cisplatin
and some related species. Clin Pharmacol Ther. 29:658–664. 1981.
View Article : Google Scholar : PubMed/NCBI
|